About: Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 06 May 2013

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2013 (ast) наукова стаття, опублікована в травні 2013 (uk) scientific article published on 06 May 2013 (en) مقالة علمية نشرت في 06 مايو 2013 (ar)
publication date	wds:Q37065849-753039C0-CCAB-47CC-8340-342C5FF93B12
publication date	2013-05-06 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37065849-FBED8356-AC12-42E2-898D-D7D3B05611B3
language of work or name	English
cites work	wds:Q37065849-03ECEDBB-B5A6-4746-80FE-C27CC7C0829E wds:Q37065849-0419B285-893A-4639-BD50-D7BF667A2480 wds:Q37065849-0CD203FF-A200-40D1-BB29-D6A5B3BE11F5 wds:Q37065849-0E8B5201-9B60-4307-8C75-191EC67C2CB5 wds:Q37065849-103A6A7A-3AFA-4A1E-BC22-541ECCE54D7D wds:Q37065849-50DA29DC-9EC9-46BF-AD52-693E36B69C12 wds:Q37065849-59369552-C0E4-46A0-B838-378467C015DF wds:Q37065849-672E7FF7-DDE4-428D-AA21-A83AF186061F wds:Q37065849-67830979-5390-4CF5-A941-0D7C07B431FD wds:Q37065849-6891BE09-72E4-459F-93BF-255C3BBA9B70 wds:Q37065849-6AB34904-4715-4ADA-B259-CC0A8B784A6F wds:Q37065849-6FFF2FF9-1E77-4BA2-8948-35BE9CFB297F wds:Q37065849-72F319D9-65A1-4524-ABC0-274DBA096FBB wds:Q37065849-916CE76A-71BA-4ED4-8447-72D9018BA21D wds:Q37065849-9C0CB6A0-6EB3-4444-88C7-13C88AE60CEA wds:Q37065849-B4DF25BC-E809-47E4-BE09-8E04A6A529F5 wds:Q37065849-BC9351BF-EACC-49C9-A655-12735AE6676A wds:Q37065849-CD7DF637-24FA-4E13-AD9C-7668E6B823FC wds:Q37065849-D2578FBC-F48F-43A6-AC56-35A6313ADB35 wds:Q37065849-E4600320-F7EB-4729-AC72-AC8FC7BC5956 wds:Q37065849-E46B119E-BBAF-4A44-8F60-3F14D9F415A5 wds:Q37065849-E73AD27C-F738-4814-BB6E-51F3AFF09063 wds:Q37065849-ECA15844-A970-4504-B155-7C92169DD088 wds:Q37065849-EE6002F9-0B4E-4725-A8F2-AB9939452BFF wds:Q37065849-F90E5162-9C19-49FF-AE4E-2902B168EBC7
cites work	PI(3)king apart PTEN's role in cancer. Treatment of HER2-positive breast cancer: current status and future perspectives. Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib A robust immunohistochemical assay for detecting PTEN expression in human tumors PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer Current and emerging targeted therapies for metastatic breast cancer PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy Measurement of PTEN expression using tissue microarrays to determine a race-specific prognostic marker in breast cancer Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer
author name string	wds:Q37065849-271AC751-891C-45DB-9AED-88032C772F00 wds:Q37065849-2F119052-47C4-49D1-A40E-8F2FEB53C49D wds:Q37065849-546377D9-83AB-4682-8875-D2BE0B615FF9 wds:Q37065849-5F360305-614F-4D00-BD52-3DA2D1A9997A wds:Q37065849-653FD99F-0EA2-44F8-AFAC-7F3BFFBE4A84 wds:Q37065849-6734879A-2B1B-4612-A9A3-358623A42B43 wds:Q37065849-70DAB25D-B008-48A1-BFF9-4A60AF792CEA wds:Q37065849-75B791BE-FE26-4249-A668-B56BA5323517 wds:Q37065849-ACCF6FB9-00F0-4CBD-9001-F8C5817D4002 wds:Q37065849-B3B01586-8294-47A7-BC3C-B431564B61E5 wds:Q37065849-E9DE5B30-697A-4D2B-8D8A-CACA109CD9E9
author name string	Lyndsay N Harris Nancy E Davidson Peter A Kaufman Julie R Gralow Ann E McCullough Beiyun Chen Monica M Reinholz Robert B Jenkins Silvana Martino Leila A Kutteh Xochiquetzal J Geiger
rdfs:label	Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial (en) Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial (nl) Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial (ast)
skos:prefLabel	Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial (en) Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial (nl) Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial (ast)
name	Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial (en)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 170 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software